ATE480563T1 - Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper - Google Patents

Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper

Info

Publication number
ATE480563T1
ATE480563T1 AT06706900T AT06706900T ATE480563T1 AT E480563 T1 ATE480563 T1 AT E480563T1 AT 06706900 T AT06706900 T AT 06706900T AT 06706900 T AT06706900 T AT 06706900T AT E480563 T1 ATE480563 T1 AT E480563T1
Authority
AT
Austria
Prior art keywords
iats
serotype
human monoclonal
lipopolysaccharides
lps
Prior art date
Application number
AT06706900T
Other languages
English (en)
Inventor
Alois Lang
Michael Horn
Martin Imboden
Adrian Zuercher
Original Assignee
Kenta Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech Ag filed Critical Kenta Biotech Ag
Application granted granted Critical
Publication of ATE480563T1 publication Critical patent/ATE480563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06706900T 2005-02-14 2006-02-13 Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper ATE480563T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (de) 2005-02-14 2005-02-14 Menschlicher Monoklonaler Antikörper, welcher spezifisch für lipopolysaccharide (LPS) von Pseudomonas aeruginosa IATS O11 ist
PCT/EP2006/001289 WO2006084758A1 (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Publications (1)

Publication Number Publication Date
ATE480563T1 true ATE480563T1 (de) 2010-09-15

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06706900T ATE480563T1 (de) 2005-02-14 2006-02-13 Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper

Country Status (11)

Country Link
US (1) US8197816B2 (de)
EP (2) EP1690875A1 (de)
JP (1) JP4944799B2 (de)
KR (2) KR20070107756A (de)
CN (1) CN101120018B (de)
AT (1) ATE480563T1 (de)
CA (1) CA2597701C (de)
DE (1) DE602006016736D1 (de)
ES (1) ES2348263T3 (de)
IL (1) IL184774A (de)
WO (1) WO2006084758A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766391A4 (de) * 2004-06-28 2008-02-20 Protcome Systems Intellectual Neue verfahren zur diagnose der behandlung einer infektion mit p. aeruginosa sowie reagentien dafür
CN102639562A (zh) * 2009-04-09 2012-08-15 肯塔生物技术有限公司 对绿脓假单胞菌的血清型iats o1的脂多糖类(lps)具有特异性的人单克隆抗体
WO2011102551A1 (en) * 2010-02-18 2011-08-25 Meiji Seika Kaisha, Ltd. Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (de) * 2010-02-26 2011-08-31 Kenta Biotech AG Verfahren und Kits zur Serotypisierung von Pseudomonas aeruginosa und Oligonukleotidsequenzen zur Verwendung in solchen Methoden und Kits
SG11201602490UA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Anti-lps o11 antibody
AU2016353073A1 (en) 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
US11969476B2 (en) 2020-04-03 2024-04-30 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2023281120A1 (en) 2021-07-09 2023-01-12 Luxembourg Institute Of Health (Lih) Dimeric protein complexes and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
MXPA02007449A (es) 2000-02-03 2003-04-14 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
WO2002020619A2 (en) * 2000-09-07 2002-03-14 Schreiber John R HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)

Also Published As

Publication number Publication date
CN101120018B (zh) 2012-07-25
KR20130018991A (ko) 2013-02-25
CA2597701A1 (en) 2006-08-17
JP4944799B2 (ja) 2012-06-06
US8197816B2 (en) 2012-06-12
CN101120018A (zh) 2008-02-06
JP2008530988A (ja) 2008-08-14
IL184774A (en) 2012-01-31
WO2006084758A1 (en) 2006-08-17
ES2348263T3 (es) 2010-12-02
IL184774A0 (en) 2007-12-03
EP1848741A1 (de) 2007-10-31
US20090068191A1 (en) 2009-03-12
EP1690875A1 (de) 2006-08-16
DE602006016736D1 (de) 2010-10-21
KR20070107756A (ko) 2007-11-07
EP1848741B1 (de) 2010-09-08
CA2597701C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
ATE480563T1 (de) Für lipopolysaccharide (lps) des pseudomonas aeruginosa-iats-o11-serotyps spezifische humane monoklonale antikörper
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
NO20074563L (no) Novel anti-plgf antibody
EA200802168A1 (ru) Гуманизированное антитело к с-kit
WO2010009987A3 (en) Diagnostic antibody assay
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
DE602006015929D1 (de) Doxorubicin-immuntest
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1848741

Country of ref document: EP